Big Pharma has lost billions of dollars recently, with plant closures and layoffs totaling 40,000 jobs so far and climbing. But the cuts in most Big Pharma companies are likely to be more, not less, as a prescription drug rehabilitation programs necessary to drive the future.
While some companies are not always going to lower the pharmaceutical interests, the closure of other facilities and the reduction of labor costs and increase profits sagging. Big Pharma, as allState-owned enterprises, is the nuts and bolts on the bottom line. Being in the business improvement of health is not a factor in the numbers game, nor is concern that millions of people in drug rehabilitation programs, or should be, because their products.
An article in the Guardian Unlimited, says that the Swiss drug manufacturer Novartis AG, the dismissal of 2,500 employees announced belongs – on a series of cuts in Big Pharma is spreading across the landscape. Last WeekSanofi-Aventis has announced in France, spending cuts, and Bristol-Myers Squibb said it will cut 10% of workers and closing several factories. Most other major pharmaceutical companies are already taking steps to avoid loss of business, including Eli Lilly, Johnson & Johnson, AstraZeneca, Pfizer, GlaxoSmithKline, Merck, Amgen and Schering-Plow – many of them names that the consultant drug rehabilitation, not only stock market investors are familiar.
Among the problems, big pharmaFaces of the research departments of production are too few new brand name drugs with patents on many brands of profitability which will soon expire. Cheaper generic drugs will replace the brand, and these gains will not go into the pockets of Big Pharma. It will sell no fewer drugs, but are more accessible. As for drugs, we will see even more dependencies and requirements for drug rehabilitation services.
Big Pharma has received have lost billions of dollars earmarked for drugs,"Black box" warnings on the labels of the FDA and more billions of dollars for drugs from the market because of the risks of life has been withdrawn. As a result, more than ever, people began to distrust of large pharmaceutical and prevention of prescription drugs that even remotely similar to drugs known dangerous.
For example, Merck withdrew its arthritis painkiller Vioxx from the market in 2004 because of serious cardiovascular side effects. The withdrawal of Merck's cost 2.5 billion dollars annually. MostThe former Vioxx users were expected to switch to Pfizer's Celebrex arthritis drug – similar to Vioxx, but also with a black-box warning. Instead, half of which Celebrex, along with all other similar provisions. Not only that Pfizer does not pick up business Vioxx, Celebrex, but 60% of his clients went away, because for safety. Pfizer's Celebrex on profits, probably 4 billion dollars a year, dropped to $ 2 billion.
Meanwhile, a new generation of drugs with cause unknown side effects or problems, drug addiction rehabilitation could be the development of biotech companies that are not big pharma players. Expect to be purchased or acquired, in principle, because these drugs was a threat to the markets of large pharmaceutical companies represented, and Big Pharma marketing infrastructure already exists. These acquisitions are usually delayed until some testing shows that it is one thing clear, secure and supplements, medicines in the areas of drugs known> Rehab centers.
Hence the need for drug rehabilitation is that, despite the increase of the cuts in Big Pharma. With millions of people already addicted to drugs and require drug detox and drug rehab now, and can go with the cheaper drugs, we expect an even greater need for facilities for drug rehabilitation program for the next few years to see .
0